Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses amyloidosis treatment and a validated composite organ and hematologic response model for early assessment of treatment outcomes in light-chain amyloidosis. Dr Kumar goes on to discuss the impact of minimal residual negativity (MRD) on outcomes in light-chain amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).